AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 89
Study 17101300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 14727272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with a basal rate of 8 mL/h and a 2 mL patient-controlled bolus available each hour (8/2 group, n = 12)
Number of subjects: 24
Study 14727272 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% with a basal rate of 4 mL/h and a 6 mL patient-controlled bolus available each hour (4/6 group, n = 12)
Number of subjects: 24
Study 11710756 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive offspring of hypertensive parents
Number of subjects: 36
Study 11710756 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study 9136839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 750 mg/day)
Number of subjects: 153
Study 9136839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 7957433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory monitoring (CRM)
Number of subjects: 93
Study 7957433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmonitoring
Number of subjects: 93
Study 7957433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of cot death)
Number of subjects: 93
Study 3066517 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin + amikacin
Number of subjects: 76
Study 3066517 — intervention group
Group type: COMPARATOR
Intervention: ceftazidime + amikacin
Number of subjects: 76
Study 3066517 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin
Number of subjects: 76
Study 3066517 — intervention group
Group type: COMPARATOR
Intervention: ceftazidime
Number of subjects: 76
Study 31619357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 278
Study 31619357 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg
Number of subjects: 278
Study 29934295 — intervention group
Group type: EXPERIMENTAL
Intervention: Single postdischarge nurse‐led home visit
Number of subjects: 1500
Study 29934295 — intervention group
Group type: COMPARATOR
Intervention: No visit (Control)
Number of subjects: 1500
Study 27568806 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcolepsy type 1 patients
Number of subjects: 24
Study 27568806 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 24
Study 27568806 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic hypersomnia patients
Number of subjects: 24
Study 25393287 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg zinc sulphate daily for three months
Number of subjects: 72
Study 25393287 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro zinc sulphate
Number of subjects: 72
Study 23559084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients
Number of subjects: 15
Study 20675620 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation (100 mg intramuscular every 2 weeks for 26 weeks)
Number of subjects: 0
Study 20675620 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 20675620 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Number of subjects: 0
Study 19610505 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G Quincke spinal needle
Number of subjects: 480
Study 19610505 — intervention group
Group type: EXPERIMENTAL
Intervention: 27G Quincke spinal needle
Number of subjects: 480
Study 19610505 — intervention group
Group type: EXPERIMENTAL
Intervention: 27G Whitacre spinal needle
Number of subjects: 480
Study 19679505 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-only exercise protocol (ECC: 5 sets of 20 contractions)
Number of subjects: 13
Study 19679505 — intervention group
Group type: COMPARATOR
Intervention: Concentric-eccentric protocol (CON-ECC: 5 sets of 10 eccentric/10 concentric contractions)
Number of subjects: 13
Study 16269634 — intervention group
Group type: EXPERIMENTAL
Intervention: AcPAO
Number of subjects: 19
Study 16269634 — intervention group
Group type: EXPERIMENTAL
Intervention: SMO
Number of subjects: 19
Study 16269634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrolein
Number of subjects: 19
Study 16269634 — intervention group
Group type: EXPERIMENTAL
Intervention: Total polyamine oxidase (AcPAO + SMO)
Number of subjects: 19
Study 16269634 — intervention group
Group type: COMPARATOR
Intervention: MRI/CT confirmation
Number of subjects: 19
Study 16269634 — intervention group
Group type: COMPARATOR
Intervention: MRI confirmation in normal subjects
Number of subjects: 19
Study 12102473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with cyclosporine (CSA) and methotrexate (MTX) plus prednisone (PDN) (group B)
Number of subjects: 24
Study 12102473 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) and prednisone (PDN) (group A)
Number of subjects: 24
Study 9587881 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diet combined with exercise and behavior therapy
Number of subjects: 0
Study 9587881 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dietary and behavioral treatments
Number of subjects: 0
Study 7527453 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (CBV regimen: cyclophosphamide, carmustine, etoposide)
Number of subjects: 464
Study 7527453 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (ifosfamide, etoposide, asparaginase, cytarabine)
Number of subjects: 464
Study 7527453 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (CBV regimen)
Number of subjects: 464
Study 7527453 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 464
Study 2737235 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.5 mg s.c. followed by metoclopramide 10 mg i.v.
Number of subjects: 6
Study 2737235 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg i.v.
Number of subjects: 6
Study 2737235 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.5 mg s.c.
Number of subjects: 6
Study 11959638 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% maximal inspiratory pressure (MIP) during the fatigue trial
Number of subjects: 6
Study 11959638 — intervention group
Group type: COMPARATOR
Intervention: Control (0% MIP, no diaphragm fatigue)
Number of subjects: 6
Study 30231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-only CPR
Number of subjects: 18
Study 30231037 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 18
Study 30231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-valve-mask ventilation
Number of subjects: 18
Study 27203508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (fluticasone furoate 100 μg and vilanterol 25 μg)
Number of subjects: 16485
Study 27203508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg)
Number of subjects: 16485
Study 27203508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (25 μg)
Number of subjects: 16485
Study 27203508 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 16485
Study 25229902 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (4 sessions of 45-65 minutes with lectures, Q&A, educational booklets, and posters)
Number of subjects: 80
Study 25229902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education intervention)
Number of subjects: 80
Study 22406878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 21718
Study 22406878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21718
Study 20363839 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (educational program plus breathing exercises plus aerobic training)
Number of subjects: 101
Study 20363839 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational program plus breathing exercises)
Number of subjects: 101
Study 17485195 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEech Pathology Intervention Program for CHronic Cough (SPEICH‐C)
Number of subjects: 82
Study 17485195 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyle Education intervention program (HLE control)
Number of subjects: 82
Study 15820588 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in voluntary associations
Number of subjects: 1504
Study 15820588 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighbourhood of residence
Number of subjects: 1504
Study 12581974 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (20 mg/d for 10 d, gradually decreased afterwards) + vitamin B + coenzyme Q10
Number of subjects: 20
Study 12581974 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B + coenzyme Q10
Number of subjects: 20
Study 10088566 — intervention group
Group type: EXPERIMENTAL
Intervention: Expandable metallic Z stent (group A)
Number of subjects: 18
Study 10088566 — intervention group
Group type: COMPARATOR
Intervention: Repeated external-internal stent placement (group B)
Number of subjects: 18
Study 8719584 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 129
Study 8719584 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 129
Study 2327531 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory method
Number of subjects: 1041
Study 2327531 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from Smoking
Number of subjects: 1041
Study 2327531 — intervention group
Group type: COMPARATOR
Intervention: FreshStart
Number of subjects: 1041
Study 7000474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg daily)
Number of subjects: 23
Study 7000474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30626222 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep-deprivation (SD)
Number of subjects: 15
Study 30626222 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep-deprivation with nap (SDN)
Number of subjects: 15
Study 30626222 — intervention group
Group type: COMPARATOR
Intervention: Normal (N)
Number of subjects: 15
Study 29510715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand More AT Work (SMArT Work) intervention including strategies like height adjustable desks, senior management support, seminars, and face-to-face coaching sessions
Number of subjects: 70
Study 27131288 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Session (HES)
Number of subjects: 0
Study 24582567 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg resveratrol daily for 8 weeks
Number of subjects: 20
Study 24582567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22205536 — intervention group
Group type: EXPERIMENTAL
Intervention: TissuGlu® surgical adhesive
Number of subjects: 20
Study 22205536 — intervention group
Group type: COMPARATOR
Intervention: Control (no TissuGlu application)
Number of subjects: 20
Study 20089104 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH PETCT imaging at 15 min after injection
Number of subjects: 25
Study 20089104 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH PETCT imaging at 60 min after injection
Number of subjects: 25
Study 18059587 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein plus carbohydrate beverage (10 g protein and 21 g fructose)
Number of subjects: 8
Study 18059587 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-only beverage (21 g fructose and 10 g maltodextran)
Number of subjects: 8
Study 16525941 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1010
Study 16525941 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1010
Study 16525941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Bisoprolol + Enalapril)
Number of subjects: 1010
Study 11868011 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) applied to the rim and any residual mucosal or submucosal tissue in the base of the polypectomy site.
Number of subjects: 34
Study 11868011 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control) after piecemeal snare resection.
Number of subjects: 34
Study 11868011 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) applied to all visible remaining adenomatous tissue in patients with incomplete excision.
Number of subjects: 34
Study 11431662 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sustained ventricular tachycardia
Number of subjects: 16842
Study 11431662 — intervention group
Group type: COMPARATOR
Intervention: No late sustained ventricular tachycardia (reference group)
Number of subjects: 16842
Study 9589654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium replete diet (160 mmol/day)
Number of subjects: 8
Study 9589654 — intervention group
Group type: COMPARATOR
Intervention: Sodium deplete diet (40 mmol/day)
Number of subjects: 8
Study 8055694 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphcon-A (naphazoline HCl 0.025% and pheniramine maleate 0.3%)
Number of subjects: 72
Study 8055694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8055694 — intervention group
Group type: COMPARATOR
Intervention: Naphazoline
Number of subjects: 72
Study 8055694 — intervention group
Group type: COMPARATOR
Intervention: Pheniramine
Number of subjects: 72
Study 2923768 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 48
Study 2923768 — intervention group
Group type: COMPARATOR
Intervention: halothane
Number of subjects: 48
Study 793524 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiation with 1% CCT ointment
Number of subjects: 0
Study 793524 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiation with 6% CCT ointment
Number of subjects: 0
Study 793524 — intervention group
Group type: EXPERIMENTAL
Intervention: UV irradiation with ointment
Number of subjects: 0
Study 793524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CCT ointment and UV irradiation
Number of subjects: 0
Study 793524 — intervention group
Group type: COMPARATOR
Intervention: High-concentration (6%) tar ointment without UV irradiation
Number of subjects: 0
Study 30264521 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-centred education
Number of subjects: 8
Study 30264521 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical models endorsed by educators
Number of subjects: 8
Study 30264521 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative approaches in education
Number of subjects: 8
Study 28406788 — intervention group
Group type: COMPARATOR
Intervention: Disease-modifying agents (DMAs) with varying characteristics including dosage type, efficacy, relapse risk, and side effects.
Number of subjects: 0
Study 25218667 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (at least 5% decrease in BMI)
Number of subjects: 43
Study 25218667 — intervention group
Group type: COMPARATOR
Intervention: No weight loss (less than 5% decrease in BMI)
Number of subjects: 43
Study 23994379 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz measles vaccine (SW)
Number of subjects: 996
Study 23994379 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb measles vaccine (EZ)
Number of subjects: 996
Study 23994379 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose at 18 months (same MV)
Number of subjects: 996
Study 23994379 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-protective antibody levels
Number of subjects: 996
Study 23994379 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison after EZ
Number of subjects: 996
Study 23994379 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal comparison
Number of subjects: 996
Study 21606827 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 70
Study 19731967 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 0
Study 19731967 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (NZ)
Number of subjects: 0
Study 19731967 — intervention group
Group type: COMPARATOR
Intervention: Symptom management alone
Number of subjects: 0
Study 16788411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tilt test
Number of subjects: 61
Study 16788411 — intervention group
Group type: EXPERIMENTAL
Intervention: Active instability test
Number of subjects: 61
Study 16788411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella alta test
Number of subjects: 61
Study 16788411 — intervention group
Group type: EXPERIMENTAL
Intervention: Apprehension test
Number of subjects: 61
Study 16788411 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps angle, lateral and medial retinacular tenderness, patellofemoral crepitation, squinting patella, and reduced mobility of the patella
Number of subjects: 61
Study 16788411 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 61
Study 16788411 — intervention group
Group type: EXPERIMENTAL
Intervention: Other radiographic measures (sulcus angle, Laurin angle, Merchant angle, Insall‐Salvati index)
Number of subjects: 61
Study 15497256 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent memory task present
Number of subjects: 0
Study 15497256 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to focus on memory
Number of subjects: 0
Study 15497256 — intervention group
Group type: COMPARATOR
Intervention: Instruction to focus on timing
Number of subjects: 0
Study 11430720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy
Number of subjects: 25
Study 10168576 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E) - received usual clinic information plus a prenatal and postpartum intervention
Number of subjects: 391
Study 10168576 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - received only usual clinic information
Number of subjects: 391
Study 8436517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rate 0.73 Gy.h‐1
Number of subjects: 204
Study 8436517 — intervention group
Group type: COMPARATOR
Intervention: Low dose rate 0.38 Gy.h‐1
Number of subjects: 204
Study 8436517 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose rate group (0.73 Gy.h‐1)
Number of subjects: 204
Study 8436517 — intervention group
Group type: COMPARATOR
Intervention: Lower dose rate group (0.38 Gy.h‐1)
Number of subjects: 204
Study 3453705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribomunyl (active medicine)
Number of subjects: 24
Study 3453705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study 31885863 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Tesla scanner
Number of subjects: 3
Study 31885863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pass filtering of time series
Number of subjects: 3
Study 31885863 — intervention group
Group type: COMPARATOR
Intervention: 1.5 Tesla scanner
Number of subjects: 3
Study 30145268 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (16 mg/day)
Number of subjects: 0
Study 30145268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26716865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation strategy (low tidal volume, PEEP between 6 and 8 cmH2O, recruitment manoeuvres)
Number of subjects: 79
Study 26716865 — intervention group
Group type: COMPARATOR
Intervention: Non-protective ventilation strategy (higher tidal volume, zero PEEP, no recruitment manoeuvres)
Number of subjects: 79
Study 26716865 — intervention group
Group type: COMPARATOR
Intervention: Non-protective ventilation strategy
Number of subjects: 79
Study 26716865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation strategy
Number of subjects: 79
Study 25134530 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based patient information (EBPI)
Number of subjects: 1120
Study 25134530 — intervention group
Group type: COMPARATOR
Intervention: Standard on-line information (Control)
Number of subjects: 1120
Study 22290107 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin
Number of subjects: 181
Study 22290107 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline-rifampin-gentamicin
Number of subjects: 181
Study 20370962 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment monotherapies, combinations, or augmentation strategies (specifics not detailed)
Number of subjects: 2876
Study 17019375 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein-containing isoflavones
Number of subjects: 216
Study 17019375 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 216
Study 15906588 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily for 14 days
Number of subjects: 47
Study 15906588 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily for 14 days
Number of subjects: 47
Study 15906588 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg and 10 mg
Number of subjects: 47
Study 12654606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban administered in the emergency room
Number of subjects: 100
Study 12654606 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban administered later in the catheterization laboratory
Number of subjects: 100
Study 12654606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (early administration)
Number of subjects: 100
Study 10473830 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical neck dissection after initial chemotherapy and between two courses of locoregional radiotherapy (group A)
Number of subjects: 44
Study 10473830 — intervention group
Group type: COMPARATOR
Intervention: Surgery after finishing chemotherapy and locoregional radiotherapy (group B 1)
Number of subjects: 44
Study 10473830 — intervention group
Group type: COMPARATOR
Intervention: Surgery after receiving only full-dose locoregional radiotherapy (group B 2)
Number of subjects: 44
Study 8733854 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 36
Study 8733854 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 36
Study 1717776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of benazepril (10 mg) and cadralazine (5 mg)
Number of subjects: 8